Anti-Neprilysin Market Analysis: Evolving Renal Health Dynamics

 The global Anti-Neprilysin Market caters to the growing need for efficient treatment of various renal and cardiovascular diseases. Anti-Neprilysin drugs have proven effective in attenuating proteinuria and slowing the progression of chronic kidney diseases. The global Anti-Neprilysin Market is estimated to be valued at US$ 1,263.3 Mn in 2023 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The substantial rise in the incidence of chronic kidney diseases across the world represents a key growth driver for the anti-Neprilysin market. Neprilysin inhibitors have emerged as a viable therapeutic approach for preventing kidney damage in various renal conditions. Ongoing clinical trials are evaluating the efficacy of anti-Neprilysin drugs such as sacubitril/valsartan in delaying kidney function decline in patients with diabetes and hypertension. Moreover, favorable regulatory framework for novel neprilysin inhibitor therapies is encouraging pharmaceutical research on this class of drugs.
Segment Analysis

The global Anti-Neprilysin market is dominated by the combination drugs sub segment. This is because combination drugs such as Sacubitril/Valsartan act synergistically by blocking both neprilysin and Angiotensin receptors, allowing for better management of conditions like heart failure. Sacubitril/Valsartan is the first approved neprilysin inhibitor for use in heart failure patients.

Key Takeaways

The global Anti-Neprilysin market is expected to witness high growth over the forecast period of 2023 to 2030. Rising prevalence of heart failure and related comorbidities globally will drive demand for neprilysin inhibiting drugs.

Regional analysis

North America currently dominates the global Anti-Neprilysin market owing to availability of advanced treatments, favorable reimbursement policies, and high awareness levels regarding neprilysin inhibiting drugs. The US holds the largest share in the regional market led by presence of major players and frequent FDA approvals. Asia Pacific is expected to witness fastest growth during the forecast period with China and India emerging as high potential markets. This can be attributed to increasing healthcare spending, growing geriatric population, and rising incidence of cardiovascular diseases.

Key players

Key players operating in the Anti-Neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, and Oceanic Pharmachem Pvt. Ltd. BIOPROJET and Novartis AG currently dominate the market with their blockbuster drug Sacubitril/Valsartan (trade name: Entresto). Pharmaleads SA is developing novel neprilysin inhibitors with improved safety profiles. Theravance Biopharm is engaged in research on next generation neprilysin inhibiting drugs for various conditions. Cipla Inc and Oceanic Pharmachem Pvt. Ltd focus on generics of Sacubitril/Valsartan.